Skip to main content

Table 2 Known genetic alterations characterizing the NSCLC lines used in the paper. Information about genetic defects were retrieved from the database of the Wellcome Trust Sanger Institute Catalogue Of Somatic Mutations In Cancer COSMIC, https://cancer.sanger.ac.uk/cell_lines)

From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

Cell line

Hystotype

Mutational status

TP53

EGFR

KRAS

Other mutations/molecular alterations

Calu-6

anaplastic carcinoma

mut

wt

Q61K

JAK1, BRCA1, p16INK4A methylation

SK-Lu-1

adenocarcinoma

mut

wt

G12D

KIT, CSF3R, FLT4

NCI-H1975

adenocarcinoma

mut

L858R + T790 M

wt

PDGFRA, PIK3CA

NCI-H2228

adenocarcinoma

mut

wt

wt

ALK translocation, PDGFRA, RB